Date: 2014-06-12
Type of information: Licensing agreement
Compound: intellectual property related to the CRISPR/Cas9 gene editing system
Company: Horizon Discovery (UK) the Broad Institute (UK)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On June 12, 2014, Horizon Discovery, an international life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. Under the terms of the agreement, Horizon has rights to use the technology commercially for applications including development of research tools and reagents, and provision of services that utilize CRISPR, for example as part of Horizon’s GENASSIST™ offering. GENASSIST is a comprehensive product and service solution for CRISPR and rAAV gene editing, including guide RNA design and validation, donor design, and a wide range of off-the-shelf plasmids. The acquisition of additional CRISPR IP is in line with the Company’s aims outlined at the time of its IPO and further strengthens Horizon’s position in the market for this cutting edge gene editing technology. Access to a broader CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D and enhance the attractiveness of the Horizon GENESIS™ offering to customers.
Financial terms:
Latest news:
